Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Retifanlimab in Selected Solid Tumors (POD1UM-203)
NCT03679767Phase 2Completed
- Sponsor
- Incyte
- Start
- Jan 2019
- Primary completion
- Apr 2021
- Modality
- Monoclonal Antibodies
- Countries
- 8
01
Overview
A Phase 2 trial of retifanlimab in non-small cell lung cancer (NSCLC), urothelial carcinoma (UC), melanoma, renal cell carcinoma (RCC), sponsored by Incyte. Started Jan 2019; status: completed.
02
Drugs
retifanlimab
03
Conditions
non-small cell lung cancer (NSCLC)urothelial carcinoma (UC)melanomarenal cell carcinoma (RCC)
Beyond the preview
Go deeper on NCT03679767.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03679767.